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Abstract
Objectives: The following observation was primarily based on the study of gene fusion in blood and bone marrow cells taken from
68 Iranian children with acute lymphoblastic leukemia (ALL), to compare with healthy population.
Methods: Peripheral blood and bone marrow samples obtained from patients with ALL were immunophenotyped to determine
the lineage and the level of differentiation. With reverse transcriptase-polymerase chain reaction (RT-PCR), the RNA molecules were
analyzed according to Van Dongen et al protocol to detect fused genes in cell population.
Results: Leukemic cell type was identified by cytochemical stains and classified on the basis of FAB classification. Nonetheless the
frequencies of E2A/PBX1, MLL/AF4, BCR/ABL (M-BCR) and BCR/ABL(m-BCR) gene transcripts were 1.5%, 0%, 0% and 4.4% respectively. The
positive case of E2A/PBX1 fusion gene had an early pre B and 3 BCR/ABL (m-BCR). Positive cases had an early pre B and pre-B ALL im-
munophenotype.
Conclusions: Early pre-B cells were the most common types in our patients. The RT-PCR was shown to be an ideal method for de-
tecting hybrid transcripts and to estimate the prevalence of the fusion genes in ALL patients. The frequency of these fusion genes
in Iranian pediatric ALL patients were found to be similar to some developed countries. Thus, their presence does not seem to be
predictive of increasing malignancy, but rather it can challenge the prognostic significance of these rearrangements.
Keywords: Childhood Acute Lymphoblastic Leukemia, Immunophenotype, Genetic Alterations
1. Background
Acute lymphoblastic leukemia (ALL) in children is a
heterogeneous disease with different subtypes based on
their cellular and molecular characteristics. ALL accounts
for approximately 80% of all acute leukemias in childhood,
contrasting with about 20% of the cases in adults (1).
Genetic molecular analysis on leukemia cell has pro-
vided the basic knowledge of pathogenesis and prognosis
in ALL. Since the translocation discovery of the first fusion
gene, BCR-ABL resulting from a t (9;22) translocation, many
fusion transcripts that occur in leukemia, such as t (12;21),
t (4;11), and t (1,19), have subsequently been detected (2,
3). Research has shown that normally-fused translocated
genes play a crucial role in the development and function
of lymphocytes and bone marrow cells (4). It has therefore
been suggested that the fusion genes may be closely corre-
lated with the onset of leukemia. The presence of MLL/AF4 is
associated with a very poor prognosis the same as E2A/PBX1
(5-8). Studies on genetic changes in leukemic cells signif-
icantly enhance the precision of diagnosis and allow de-
termining treatment strategy for childhood ALL, especially
when specific aberrations are present.
2. Methods
This study was done to detect blast cells taken at early
diagnosis from 68 patients with ALL in Children’s Medical
center. Tehran, Iran. Diagnosis was based on the classifi-
cation of French American British (FAB) criteria and cyto-
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chemistry staining. Informed consent was obtained prior
to peripheral blood and bone marrow aspiration.
Immunophenotyping: The leukemic cells were im-
munophenotyped using monoclonal antibodies to define
the lineage and to determine the level of differentiation.
The panel included: CD34, CD45, HLA-DR, CD117, CD10, CD19,
CD4, CD7, CD8, CD38, Tdt, CD2, CD3, CD20 and CD22. Anti-
gen expression was determined by indirect immunofluo-
rescence (BD, FACSCalibur) evaluated by flow cytometry (9,
10).
Isolation of mononuclear cells from the collected sam-
ples was performed by Ficoll Hipaque density gradient cen-
trifugation (Sigma Diagnostics) and total RNA was isolated
from the thawed cells by Trizol method according to manu-
facturer’s instructions. The total RNA was run on a agarose
gel containing ethidium bromide to visualize integrity of
bands. Thus, reverse-transcription and PCR amplification
of E2A/PBX1, MLL/AF4, M-BCR and m-BCR fusion genes were
carried out according to a standardized protocol by Van
Dongen and colleagues (11). Moreover, all cases were com-
pared with positive and negative controls. The specific
primers for RT-PCR analysis of these fusion genes are as
shown in Tables 1-4.
Table 1. The Primers for E2A/PBX1
Primer Code 5’ Position (Size) Sequence 5’- 3’
E2A-A 1434 (19) CACCAGCCTCATGCACAAC
PBX-B 675 (19) TCGCAGGAGATTCATCACG
E2A-C 1479 (19) CACCCTCCCTGACCTGTCT
PBX-D 636 (19) GGCCTGCTCGTATTTCTCC
PBX-E3’ 748 (19) TGAACTTGCGGTGGATGAT
Table 2. The Primers for MLL/AF4
Primer Code 5’ Position (Size) Sequence 5’- 3’
MLL-A 3916 (17) CCGCCTCAGCCACCTAC
AF4-B 1714 (20) TGTCACTGAGCTGAAGGTCG
MLL-C 3936 (18) AGGACCGCCAAGAAAAGA
AF4-D 1677 (20) CGTCCTTGCTGAGAATTTG
MLL-E5’ 3793 (18) AAGCCCGTCGAGGAAAAG
3. Results
During the Period of the study between 2009 and 2015,
68 new cases of ALL had been registered in Tehran. Iran,
the results of the peripheral blood and bone marrow ex-
aminations of all 68 pediatric patients prior to the start of
chemotherapy are summarized in Table 5. The table shows
Table 3. The Primers for M-BCR
Primer Code 5’ Position (Size) Sequence 5’- 3’
BCR-b1-A 3086 (22) GAAGTGTTTCAGAÅGCTTCTCC
ABL-a3-B 458 (21) GTTTGGGCTTCACACCATTCC
BCR-b2-C 3126 (21) CAGATGCTGACCAACTCGTGT
ABL-a3-D 441 (21) TTCCCCATTGTGATTATAGCCTA
ABL-a3-E3’ 505 (23) TGACTGGCGTGATGTAGTTGCTT
Table 4. The Primers for m-BCR
Primer Code 5’ Position (Size) Sequence 5’- 3’
BCR-e1-A 1479 (21) GACTGCAGCTCCAATGAGAAC
ABL-a3-B 458 (21) GTTTGGGCTTCACACCATTCC
BCR-e1-C 1602 (21) CAGAACTCGCAACAGTCCTTC
ABL-a3-D 441 (23) TTCCCCATTGTGATTATAGCCTA
ABL-a3-E3’ 505 (23) TGACTGGCGTGATGTAGTTGCTT
the data for all morphologic, immunologic and genetic
studies of cases for diagnosis as well as the outcomes of sev-
eral years’ treatment with control. Among the 68 patients
evaluated, 45 (44.1%) were male and 23 (33.9%) were female.
Blood counts with differential and bone marrow aspi-
ration analysis usually confirmed the diagnosis of ALL. The
major clinical findings included anemia. hepatomegaly
and splenomegaly. The most important laboratory results
(Table 6) were white blood cell (WBC) < 5000 (22%), 5000-
10000 (23.6%). 10000-50000 (41.2%) and > 50000 (13.2%),
and hemoglobin (Hb) < 5 (10.3%), 5 - 10 (67.7%) and > 10
(22%). Patient’s age was mainly 1 - 4 and 4 - 10 years. For
molecular analysis, we used published experiences to opti-
mize PCR program also by using agarose gel as a powerful
separation method based on the detection of presence or
absence of the target sequence and length of the fragment;
in fact we analyzed DNA fragments generated by RT-PCR
following the standard protocols of agarose gel prepara-
tion and loading the products to the gel. The final pictures
were used to detect the fusion genes and different controls.
Finally, E2A/PBX1 was positive only in patient 14 and nega-
tive in the other patients. MLL/AF4 and M-BCR were nega-
tive in them, and m-BCR was positive in patients 61, 67, 68
and negative in the others. In follow up, 44 patients were
in complete remission stage, 6 relapsed and 18 died (Table
5). Based on FAB classification of ALL in our results, 47 indi-
viduals were of type L1; 11, L2; 4, L3 and 6 assumed as ALL.
Table 7 shows the relationship between fusion genes
and ALL immunophenotypes. In this study early pre-B
was the most common in the newly diagnosed patients
(27 cases) followed by pre-B (21 cases), and T-ALL (8 cases)
types. Other cases included two pro-B ALL, two early pre-B
2 Iran J Pediatr. In Press(In Press):e5371.
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with CD13 and CD33, two early pre-B along with CD13, two
pre B plus CD7, one pre-B with CD33, one with B+T lym-
phoid cells and two with B-ALL. The prevalence of E2A/PBX1,
MLL/AF4,BCR/ABL (M-BCR)andBCR/ABL (m-BCR) in childhood
ALL were 1.5% (1/68), 0% (0/68), 0% (0/68) and 4.4% (3/68) re-
spectively.
Table 6. FAB Classification and Association with Age, WBC Count, Hemoglobin and
Outcome in ALL Patients
Patients
Age, year
1 - 10 62
> 10 6
WBC Count, *103 /ml
< 50 59
50 - 100 4
> 100 5
Hemoglobin, g/dl
< 5 7
5 - 10 46
> 10 15
Gender
Male 45
Female 23
Outcome
C.R 44
Relapse 6
Died 18
French-American British classification
L1 47
L2 11
L3 4
ALL 6
4. Discussion
Using the gene expression profiling showed a great
promise in classification of human hematopoietic malig-
nancies (12-14). Of the four markers studied in the present
work, we identified only the BCR-ABL (m-BCR) and E2A/PBX1
rearrangements in the peripheral blood and/or bone mar-
row samples obtained in 4 (6.15%) out of the 68 cases di-
agnosed with ALL during the period of study. As we know
RT-PCR has become a powerful tool in molecular analy-
sis. As we know RT-PCR has become a powerful tool in
molecular analysis and the procedure of diagnostic pro-
cess in childhood ALL may determine the prognostic fac-
tors, it can be used for risk stratification and selection of
treatment as well. The identification of prognostic factors
in ALL requires application of immunologic, hematologic
and molecular techniques (8, 10, 11, 15, 16).
For leukemic cells, immunophenotype is the main
prognostic factor in ALL, determined by lineage specific
monoclonal antibodies against various clusters of differ-
entiation markers on human leukocytes. T cell ALL used to
be considered as a poor prognostic factor. However, in the
study, here were no significant differences between groups
of patients with B-lineage or T-lineage ALL, because a few
number of patients had a relation with T-ALL. Age, Hb, WBC
and subtypes of ALL are the other known clinical and hema-
tological prognostic factors.
Age, is found to have a strong impact on outcome in
childhood ALL. In our study there were no significant dif-
ferences found among patients aged 1 to more than 10
years. On the other hand, there were on significant differ-
ences in survival rates between patients with WBC under
or over 25x103/µl.
In childhood ALL, a strong negative prognostic factor
was shown in MLL gene rearrangement (5, 6, 17). The most
common rearrangement of MLL is a balanced transloca-
tion t (4;11), associated with the expression of MLL/AF4 fu-
sion gene, high WBC and pro-B ALL immunophenotype. In
our study, there was noMLL/AF4 fusion gene in the patients,
which contrasted to report of Trka J, et al. (18), but it did not
contrast with the opinions of Soszynska K et al. (19) and Wu,
et al. (20).
In about 5% of children, E2A/PBX1 is expressed with
early pre-B ALL and poor prognosis. In our data, E2A/PBX1
was present in only one (1.5%) child with early pre-B-ALL
who achieved early hematological response with complete
remission and after that showed hematological relapse
and died. Nevertheless, it is associated usually with poor
or a better prognosis when ALL is treated more intensively
in this fusion gene (19, 21-23), but the death risk in these pa-
tients was 2.5 times higher than in the whole study group
(19). In the opinion of Soszynska K et al. (19), E2A/PBX1
was expressed in about 2.8% of children which is in agree-
ment with our findings. E2A/PBX1 expression was reported
by Zuo YX et al. (24) in about 17.5% and by Mesquita DR
et al. (25) in 9.7% of children which indicate a significant
difference with our study of 68 Iranian ALL patients with
Philadelphia chromosome analyzed for lineage involve-
ment, 3 were BCR/ABL positive.
In the Study by Zuo YX et al. (24) the frequency of
BCR/ABL positive was 13.7% which contrasted to our report.
Cetin Z et al. (26) reported with M-BCR in 1.4% which indi-
cates a significant difference to our data and with m-BCR
Iran J Pediatr. In Press(In Press):e5371. 3
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Table 7. Fusion Gene Analysis and FAB Classification Compared with Different Immunophenotypes in ALL Ppatients
Immunophenotype Patients E2A/PBX1 Positive MLL/AF4 Positive BCR/ABL (M-BCR) Positive BCR/ABL (m-BCR) Positive L1 L2 L3 ALL
Pro-B 2 0 0 0 0 1 1
Early Pre-B 27 1 0 0 1 21 5 1 1
Early Pre-B with CD13 2 0 0 0 0 1 1
Early Pre-B with CD13 and CD33 2 0 0 0 0 1 1
Pre-B 21 0 0 0 2 14 3 1 2
Pre-B with CD7 2 0 0 0 0 1 1
Pre B with CD33 1 0 0 0 0 1
T Cell 8 0 0 0 0 6 1 1
B Cell 2 0 0 0 0 2
B+T Cell 1 0 0 0 0 1
in 3.6% which did not contrast our findings. In the opin-
ion of Qin YZ et al. (27) M-BCR and m-BCR were expressed
in 4.8% and 9.1% of children with ALL respectively, indi-
catinng a significant difference with our results. Moreover,
Soszynksa K et al. (19) described 2.9% of children with ALL
had BCR/ABL fusion gene which did not contrast to our
study.
4.1. Conclusions
Our Study reveals a lower frequency of E2A/PBX1 and
BCR-ABL (m-BCR) fusion genes in childhood ALL and ab-
sence of MLL/AF4 and BCR-ABL (M-BCR) fusion genes in pedi-
atric ALL Patients. The results were confirmed by RT-PCR for
detecting hybrid transcripts. Therefore, fusion transcript
levels in untreated acute lymphoid leukemia patients were
important to estimate the frequency or prevalence of these
fusion genes in Iranian pediatric ALL patients. We can say,
1) these fusion genes are likely to be showing the transient
genomic instability and/ or 2) possibly they do not define
truly clinically apparent disease but rather malignant pro-
gression seems to depend on additional factors like the oc-
currence of oncogenic secondary changes as well as other
agents with their effects on hematopoietic microenviron-
ment. Thus, the presence of fusion genes does not seem to
be predictive of increasing malignancy, rather it can chal-
lenge the prognostic significance of these rearrangements
and lastly, improved strategies are necessary for the treat-
ment of acute leukemia patients.
Supplementary Material
Supplementary material(s) is available here [To read
supplementary materials, please refer to the journal web-
site and open PDF/HTML].
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Table 5. The Clinical and Hematological Data of ALL Patients and Gene Analysis Results in Study Subjects
Patient Age at Diagnosis
(yr.mo/sex)
Hb g/dl WBC (X103µl) Type of ALL Immunopheno-
Type
T (1.19) E2A/ PBX1 T (4;11) MLL/ AF4 T (9;22) M-BCR T (9;22) m-BCR Outcome
1 4.10/F 5.3 41280 L2 Pre B ALL - - - - Died
2 4.1/F 6.6 8170 L1 Early - - - - CR
3 9/F 8 11200 L1 Pre B ALL - - - - Died
4 3.10/F 4.9 18400 L1 Pro B ALL - - - - CR
5 3.5/M 5.9 35020 L1 Early Pre B ALL - - - - CR
6 4/M 9.1 22200 ALL Pre B ALL - - - - Relapse
7 4/M 6.3 22640 L1 Early Pre B ALL along
CD13
- - - - Died
8 6.10/F 8.9 7000 L1 Early Pre B ALL - - - - Died
9 7.9/F 7.5 4300 L1 Early Pre B - - - - Died
10 3.5/M 6.7 173300 L2 T- ALL - - - - CR
11 2/M 7 29330 L1 Early Pre B ALL - - - - CR
12 3/F 11.8 8380 L1 Pre B ALL - - - - CR
13 4/M 10.8 12170 L2 Early Pre B ALL - - - - Died
14 7/M 8.1 29450 L2 Early Pre B ALL + - - - Died
15 3/F 4.6 16000 L1 Pre B ALL - - - - CR
16 1.7/M 5.9 7620 L1 Early Pre B ALL - - - - CR
17 2.5/M 10.8 13490 L1 Early Pre B ALL - - - - Died
18 8/M 10.8 24140 L1 T-Cell ALL - - - - Relapse
19 3.2/F 10 6320 L3 Early Pre B ALL - - - - Died
20 8.2/M 9.5 2680 L1 Early Pre B ALL - - - - Died
21 3.7/M 8.1 3600 L2 Early Pre B ALL - - - - CR
22 2/M 10.4 1540 L3 Pre B ALL - - - - Died
23 11/F 11.9 16600 ALL Pre B ALL - - - - CR
24 3/M 6.2 39700 L1 Early Pre B ALL - - - - CR
25 4.5/M 10.1 5100 L1 Pre B ALL - - - - CR
26 2/F 7.6 79600 L1 Early Pre B ALL - - - - CR
27 1.5/M 7.9 10500 L1 Pre B ALL - - - - CR
28 2/M 10.5 7600 L1 Pre B ALL - - - - CR
29 8/F 6.2 12700 L1 Early Pre B ALL - - - - CR
30 2/F 8.7 3800 L2 Early Pre B ALL - - - - CR
31 7/M 8.8 15560 L1 T ALL - - - - CR
32 4/M 5.3 1470 L1 Pre B ALL - - - - CR
33 2/M 11 2530 L1 Early Pre B ALL - - - - CR
34 1/F 13.1 7150 L1 Pre B ALL - - - - CR
35 12/F 4.2 14210 ALL Early Pre B ALL - - - - CR
36 2/M 7.9 5790 L1 Early Pre B ALL - - - - Relapse
37 6/M 10.8 113180 L1 T ALL - - - - CR
38 3/M 7.9 11150 L1 Early Pre B ALL - - - - CR
39 5/M 5.6 19710 L2 Pre B ALL - - - - CR
40 3/M 10.8 6680 L1 T ALL - - - - CR
41 2/M 7.5 3260 L1 Pre B ALL - - - - CR
42 11/M 5.2 14300 L1 Pre B ALL - - - - Died
43 5/M 7.1 9770 L1 Pre B ALL - - - - Died
44 11/M 5.7 3800 L2 Early Pre B ALL - - - - Died
45 9/M 10.9 16800 L2 Early Pre B with
CD13and CD33
- - - - CR
46 5/F 3.3 5790 L1 Early Pre B ALL - - - - CR
47 4/F 8.1 1700 L1 B+T lymphoid cells - - - - CR
48 2/M 10.6 14260 L1 Pre B - - - - CR
49 13/M 5.7 231740 ALL Pre B with CD7 - - - - CR
50 8/F 9 7720 L1 Pre B with CD33 - - - - CR
51 10/M 6.4 17450 ALL T-ALL - - - - CR
52 6/M 6.9 84610 L1 Early Pre B - - - - CR
53 2/M 10 2450 L1 Early Pre B - - - - CR
54 4/F 6.9 3940 L1 Early Pre B With CD13
and CD33
- - - - CR
55 3/F 5 7730 L3 B-ALL - - - - CR
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56 2/F 5.3 940 L1 Pre B ALL - - - - CR
57 3/F 4.4 40540 ALL Pre B ALL - - - - CR
58 3/M 8.7 21650 L3 B-ALL - - - - Died
59 4/M 8.2 6380 L1 Early Pre B - - - - CR
60 4/M 7.1 13510 L1 Early Pre B - - - - CR
61 3/F 4.9 52300 L1 Early Pre B - - - + Relapse
62 8/M 6.4 6180 L1 T-ALL - - - Died
63 4/M 5.5 101000 L2 Early Pre B with CD13 - Relapse
64 14/M 8.4 365000 L1 T-ALL
(more compatible
with early cortical
T-cell ALL)
- - - - CR
65 12/M 11.3 2007 L1 Pre BALL with CD7 - - - - Relapse
66 7/M 8.9 6500 L1 Early Pre B - - - - Died
67 8/M 10 12000 L2 Pre B - - - + CR
68 6/M 4.9 3800 L1 Pre B - - - + Died
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